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Leucine‑rich alpha‑2 glycoprotein (LRG) may be a novel serum biomarker for patients with 
inflammatory bowel disease. The association of LRG with the endoscopic activity and predictability 
of mucosal healing (MH) was determined and compared with those of C‑reactive protein (CRP) and 
fecal markers (fecal immunochemical test [FIT] and fecal calprotectin [Fcal]) in 166 ulcerative colitis 
(UC) and 56 Crohn’s disease (CD) patients. In UC, LRG was correlated with the endoscopic activity and 
could predict MH, but the performance was not superior to that of fecal markers (areas under the curve 
[AUCs] for predicting MH: LRG: 0.61, CRP: 0.59, FIT: 0.75, and Fcal: 0.72). In CD, the performance of 
LRG was equivalent to that of CRP and Fcal (AUCs for predicting MH: LRG: 0.82, CRP: 0.82, FIT: 0.70, 
and Fcal: 0.88). LRG was able to discriminate patients with MH from those with endoscopic activity 
among UC and CD patients with normal CRP levels. LRG was associated with endoscopic activity and 
could predict MH in both UC and CD patients. It may be particularly useful in CD.
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Inflammatory bowel disease (IBD) is a chronic idiopathic intestinal disorder that includes two forms of condi-
tions: ulcerative colitis (UC) and Crohn’s disease (CD). Several etiologies of both these diseases have been found, 
but a complete cure has remained difficult to achieve. Therefore, continuous treatment accompanied by the 
appropriate assessment of the disease activity is necessary.
Imaging tests, particularly endoscopy, are the gold standard for assessing the disease activity, but it is impor-
tant to use non-invasive and repeatable biomarkers in daily clinical practice. In particular, predicting mucosal 
healing (MH) with biomarkers is a mandatory clinical procedure, as the absence of symptoms does not always 
indicate  MH1,2.
There have been many biomarkers developed that reflect the disease activity in patients with IBD. C-reactive 
protein (CRP) was the first acute-phase protein to be described and is an exquisitely sensitive systemic marker 
of inflammation and tissue damage. CRP is produced in the liver, and stimulation of the cytokine interleukin 
(IL)-6 is essential for inducing its  expression3. This serum marker has often been used to assess the IBD activity 
but sometimes fails to reflect the disease activity, given that the pathogenesis of these diseases are not always 
dependent on IL-6. CRP has been reported to predict MH with a sensitivity of 0.77–0.82 and specificity of 
0.32–0.40 for  UC4,5, and a sensitivity of 0.83–0.92 and specificity of 0.70–0.89 for  CD5,6. However, the low cut-off 
values (0.08–0.5 mg/dL for UC and 0.03–0.7 mg/dL for CD)4–10 may be inconvenient for use in clinical practice.
Fecal markers have frequently been used for patients with IBD. Fecal calprotectin (Fcal) in particular has 
abundant evidence regarding its correlation with the disease activity of IBD. Previous reports have demonstrated 
a sensitivity of 0.54–1.00 and specificity of 0.67–0.90 for the prediction of MH in  UC4,11–15 and a sensitivity of 
0.42–0.96 and specificity of 0.71–0.83 for the prediction of MH in CD with ileal  disease6,12,14,16,17. The fecal immu-
nological test (FIT) have shown an equivalent ability to Fcal for predicting MH in UC (sensitivity of 0.92–0.94 
and specificity of 0.62–0.79)11–15,18, although the specificity for predicting MH in CD was relatively low (sensitivity 
of 0.88–0.96 and specificity of 0.36–0.48)12,16.
Leucine-rich alpha-2 glycoprotein (LRG) is a novel serum biomarker for various diseases found by using a 
proteomics approach in patients with rheumatoid  arthritis19. Serum LRG was reported to be elevated in vari-
ous autoimmune diseases with levels correlating to the disease activity in rheumatoid arthritis, systemic lupus 
erythematosus, adult-onset Still’s disease, systemic juvenile idiopathic arthritis, primary biliary cholangitis, and 
 IBD19–26. The upregulation of LRG is associated with not only IL-6 but also IL-1β, TNFα, IL-22, etc., and the 
protein is produced in inflamed organs as well as in the  liver27,28. Previous studies have reported that levels of 
serum LRG were better correlated with the disease activity of UC than  CRP21,23.
However, no previous studies have described a detailed sensitivity analysis of LRG for predicting MH in UC 
and drew no comparison between LRG and fecal markers in the prediction of MH and the endoscopic activity. 
In addition, no reports have described the correlation between LRG and the CD activity.
Therefore, in the present study, we investigated the association of LRG with the endoscopic activity of IBD 
and the predictability of the marker for MH compared with the performance of CRP and fecal markers.
Materials and methods
Patients. All IBD patients who underwent colonoscopy or balloon-assisted enteroscopy (BAE) at Okayama 
University Hospital between November 2015 and November 2019 with serum and stool samples obtained on the 
day endoscopy were considered eligible. All UC patients and CD patients with colonic disease alone underwent 
colonoscopy, while CD patients who had lesions in the small bowel received BAE. All patients provided blood 
samples for the determination of serum LRG and CRP on the day of endoscopy. In addition, all patients were 
asked to collect, at home, two stool samples within 2 days before endoscopy and bring them to the hospital on 
the day of endoscopy for the determination of FIT and Fcal. The clinical characteristics of the patients, including 
the age at the diagnosis, sex, disease location, and current medications, were also recorded. The analyses were 
confined to a single endoscopy per patient. For patients with more than one endoscopy during the study period, 
the data of the first endoscopy was used.
The exclusion criteria were insufficient stool collection, having had a colostomy or ileostomy and failure to 
achieve full endoscopic observation for the patient’s lesions. Patients with other diseases that could affect the 
levels of LRG and CRP, including extraintestinal complications, collagen disease, heart failure, primary biliary 
cholangitis, infectious disease, and malignancy, at the time of endoscopy were excluded.
The clinical disease activity for UC patients was evaluated using the Mayo subscores for stool frequency (0, 
normal number for this patient; 1, 1–2 stools more than normal; 2, 3–4 stools more than normal; and 3, ≥ 5 stools 
more than normal) and rectal bleeding (0, no blood seen; 1, streaks of blood with stool less than half the time; 
2, obvious blood with stool most of the time; and 3, blood alone passes)29. Clinical remission was defined as a 
Mayo stool frequency subscore of 0 or 1 and a Mayo rectal bleeding subscore of  030. The clinical disease activity 
for CD patients was evaluated using the Crohn’s disease activity index (CDAI), with clinical remission defined 
as a CDAI < 150.
Endoscopy procedures and the assessment of the endoscopic disease activity. Bowel prepara-
tion was performed with a polyethylene glycol-based or magnesium citrate-based electrolyte solution according 
to the standard protocol of our hospital. After the colonic lavage fluid had been cleared, the patients underwent 
colonoscopy or BAE. All BAE examinations were performed via the transanal route.
The endoscopic status of the UC patients was assessed according to the Mayo Endoscopic Subscore (MES) 
 classification29. The MES is a four-point scale (0–3). The evaluation of MES was performed at each portion of 
the colorectum (cecum and ascending colon combined, transverse colon, descending colon, sigmoid colon, and 
rectum), and the maximum score in the colorectum of each patient was used for the analysis. Complete MH 
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was defined as MES of 0, and MH was defined as MES of 0 or 1 throughout the colorectum. In addition, active 
inflammation was defined as MES 2 or 3.
For CD patients, the endoscopic assessment was scored according to the modified simple endoscopic score 
for Crohn’s disease (mSES-CD), which was modified for the evaluation of small bowel lesions as well as colonic 
lesions based on the original SES-CD31. The small intestine was divided into two segments: distal and proximal 
ileum. The distal ileum was defined as the portion of the ileum within 40 cm from the ileocecal valve or anas-
tomosis, whereas the proximal ileum was defined as the deeper part of the ileum ≥ 40 cm proximal from those 
 points32 mSES-CD was calculated by summing the scores of six bowel segments (proximal and distal parts of 
small intestine, right colon, transverse colon, left colon, and rectum). We excluded the scoring item “strictures” 
from the original SES-CD because it represents bowel damage rather than active inflammation. Thus, we evalu-
ated the scores for the size of ulcers, ulcerated surface, and affected surface in each  segment6,33. In addition, 
regarding anastomotic lesions, only ulcers (size score > 2) were defined as being derived from CD. Complete 
MH was defined as mSES-CD of 0, MH was defined as mSES-CD of 0–2, and active inflammation was defined 
as mSED-CD > 6. For additional analysis, mSES-CD including the strictures score was also used.
All endoscopic examinations were performed by experienced endoscopists, who scored the endoscopic find-
ings with the results of the serum and fecal markers blinded.
The measurement of serum LRG levels. The serum samples were collected by centrifuging blood sam-
ples at 1500 rpm for 15 min, dividing them into aliquots, and storing them frozen at − 80 °C until use. The serum 
LRG levels were analyzed in the in-hospital laboratory using NANOPIA LRG (SEKISUI MEDICAL Company 
Limited, Tokyo, Japan). The measuring regents were provided by Laboratory for SEKISUI MEDICAL Company 
Limited. The Laboratory for Sekisui Medical covered the cost of the regent for measuring LRG.
The FIT analysis. The details of the method used for the FIT analysis have been described  previously11,18. 
In brief, the patients prepared fecal samples using a Hemodia sampling probe (Eike Chemical, Tokyo, Japan). 
The submitted stool samples were immediately processed and examined using an OC-Sensor DIANA (Eiken 
Chemical) system, which can accurately measure fecal hemoglobin at concentrations of 50 to 1000 ng/mL. Fecal 
specimens with a hemoglobin concentration of > 1000 ng/mL were measured following dilution. Because FIT is 
not accurate for measuring hemoglobin concentrations of < 50 ng/mL, the specimens with a hemoglobin con-
centration within this range (0–50 ng/mL) were handled as category.
The Fcal analysis. The fecal samples collected by the patients were stored at − 30 °C until shipment to the 
laboratory, where a calprotectin analysis was performed. The samples were sent to BML (Tokyo, Japan), where 
the level of calprotectin in the stool specimens was measured with a fluorescence enzyme immunoassay using 
Phadia EliA™ Calprotectin 2 (Thermo Fisher Scientific, Phadia AB, Uppsala, Sweden).
Pathologic findings. In UC cases, histologic studies were evaluated using the Geboes  score34 by a certifi-
cated pathologist. According to the scoring system, histologic disease activity of UC was classified into 6 grades 
from grade 0 to grade 5. For cases with endoscopic activity, the biopsy specimen from the site with maximum 
endoscopic activity was evaluated, while for remission cases, the biopsy specimen from the rectum was analyzed. 
Histological remission was defined as < Geboes score 2.1.
Statistical analyses. Statistical analyses were conducted using the JMP software program, version 14.0 
for Windows (SAS Institute Inc., Cary, NC, USA) and Stata/MP4, version 16.1 (Stata Corp. College Station, 
TX, USA). Spearman’s rank correlation test was performed to determine the correlation coefficient between the 
levels of the serum/fecal markers. The trend between the serum/fecal markers and the endoscopic scores was 
evaluated using the Jonckheere–Terpstra test. A receiver operating characteristics curve (ROC) analysis was 
used to assess the discriminatory performance of FIT, Fcal, LRG, and CRP for detecting the endoscopic status. 
The results were expressed as the area under the curve (AUC) with sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) with 95% confidence intervals (CIs). The cut off levels of LRG 
for complete MH using ROC analysis were ‘12.7 µg/mL’ for MES 0 in UC patients and ‘13.7 µg/mL’ for mSES-CD 
0 in CD patients. Hence, the cutoff value of LRG was determined for prediction of complete MH in this study 
(13 µg/mL) for convenience in clinical use of both UC and CD. The cutoff values of the other biomarkers were set 
based on previous reports (CRP: 0.20 mg/dL, FIT: 100 ng/mL, and Fcal: 200 µg/g)4–18,23. In addition, AUC values 
for complete MH were compared with the statistical method described in the  reference35. All p-values were two-
sided. p-values of < 0.05 were considered to indicate statistical significance. The data underlying this article will 
be shared on reasonable request to the corresponding author.
Ethical considerations. This study was approved by the Institutional Review Board of Okayama Univer-
sity Graduate School of Medicine (IRB number: 1904-035) conducted in accordance with the Declaration of 
Helsinki. All research was performed in accordance with relevant guidelines/regulations. Informed consent was 
obtained from each patient and/or their legal guardians.
Results
Clinical characteristics of the patients. A total of 222 endoscopies that were accompanied by corre-
sponding biomarkers results were performed in 166 UC patients (79 men and 87 women; median age at the UC 
diagnosis, 33 years) and 56 CD patients (34 men and 22 women; median age at the diagnosis, 23 years).
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The clinical characteristics and values of biomarkers of analyzed patients are summarized in Table 1. For UC 
patients, among 166 cases, 142 (86%) were in clinical remission, while the other 24 (14%) had clinically active dis-
ease. The colonoscopy findings were MES 0 in 77 (46%) cases, MES 1 in 57 (34%) cases, MES 2 in 25 (15%) cases, 
and MES 3 in 7 (4%) cases. The median (interquartile range [IQR]) value of the biomarkers was 11.6 (9.7–14.5) 
μg/mL for LRG, 0.06 (0.03–0.14) mg/dL for CRP, 50 (50–170) ng/mL for FIT, and 114 (35.1–283) μg/g for Fcal.
Table 1.  Characteristics of the study patients, colonoscopy findings and results of serum/fecal markers. UC 
ulcerative colitis, CD Crohn’s disease, IQR interquartile range, MES Mayo endoscopic subscore, mSES-CD 
modified simple endoscopic score for Crohn’s disease. *Clinical remission was defined as a Mayo stool 
frequency subscore of 0 or 1 and a Mayo rectal bleeding subscore of 0 for UC, and Crohn’s disease activity 
index (CDAI) < 150 for CD. **Of the total 166 UC cases, 158 underwent biopsy for pathological examinations.
UC CD
Patients
Total n = 166 (%) n = 56 (%)
Gender
 Male/Female 79 (48)/87 (52) 34 (61)/22 (39)
Median (IQR) age at diagnosis (years) 33 (22–44) 23 (18–35)
Number of endoscopy procedures
1/2/> 3 133 (80)/26 (16)/7 (4) 51 (91)/5 (9)/0 (0)
UC disease location
 Pancolitis/left-sided/proctitis 105 (63)/47 (28)/14 (8)
CD disease location
 L1: ileal/L2: colonic/L3: ileocolonic 14 (25)/14 (25)/28 (50)
CD disease behavior
 B1: inflammation/B2: structuring/B3: penetrating 24 (43)/20 (36)/12 (21)
 Perianal disease 17 (30)
 Previous intestinal resection 25 (45)
Endoscopy
Total colonoscopy/Balloon-assisted enteroscopy 166(100)/0 (0) 26 (46)/30 (54)
Median (IQR) duration of disease (months) 125 (51–213) 113 (45–222)
Median (IQR) age of undergoing endoscopy (years) 44 (34–57) 40 (28–47)
Clinical activity*
 Remission stage/Active stage 142 (86)/24 (14) 43 (77)/13 (23)
Indication for endoscopy
 Evaluation of disease 47 (84)
 Surveillance 3 (5)
 Stricture dilation 6 (11)
Concomitant medications
 5-aminosalycylic acid 147 (88) 49 (88)
 Corticosteroids 9 (5) 3 (5)
 Thiopurine 72 (43) 22 (39)
 Tacrolimus 6 (4) 0 (0)
 TNFα antagonist 21 (13) 33 (59)
Vedolizumab 3 (2) 0 (0)
 Ustekinumab 0 (0) 3 (5)





 Geboes score 0/1/2/3/4/5 31(20)/41(26)/11(7)/26(16)/29(18)/20(13)
Values of biomarkers, median (IQR)
 Leucin rich glycoprotein (µg/mL) 11.6 (9.7–14.5) 14.1 (9.6–17.8)
 C-reactive protein (mg/dL) 0.06 (0.03–0.14) 0.12 (0.04–0.28)
 Fecal immunochemical test (ng/mL) 50 (50–170) 50 (50–210)
 Fecal calprotectin (μg/g) 114 (35.1–283) 196 (76.8–837)
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For CD patients, among 56 endoscopy cases, 43 (77%) were in clinical remission, while the other 13 (23%) 
had clinically active disease. The endoscopy findings were mSES-CD 0 in 19 (34%) cases, mSES-CD 1–2 in 7 
(13%) cases, mSES-CD 3–4 in 9 (16%) cases, mSES-CD 5–10 in 15 (27%) cases, and mSES-CD 11–15 in 6 (11%) 
cases. The median (IQR) value of biomarkers was 14.1 (9.6–17.8) μg/mL for LRG, 0.12 (0.04–0.28) mg/dL for 
CRP, 50 (50–210) ng/mL for FIT, and 196 (76.8–837) μg/g for Fcal.
Correlation between LRG and other biomarkers in IBD patients. The correlations between LRG 
and other biomarkers (CRP, FIT, and Fcal) were analyzed The Spearman’s rank correlation coefficients for UC 
and CD were as follows; CRP (Fig. 1A) UC: r = 0.43, p < 0.0001, CD: r = 0.64, p < 0.0001, FIT (Fig. 1B) UC: r = 0.29, 
p = 0.0002, CD: r = 0.42, p = 0.0011, and Fcal (Fig. 1C) UC: r = 0.25, p = 0.0014, CD: r = 0.61, p < 0.0001. In particu-
lar, the correlation coefficient between CRP and LRG was higher than those between fecal markers and LRG.
Correlations between serum/fecal biomarkers and colonoscopic findings in UC patients. The 
correlations between serum/fecal biomarkers and colonoscopic findings (maximum MES in the colorectum) 
were analyzed. The trend between the serum/fecal markers and the MES was statistically significant except for 
CRP (Jonckheere-Terpstra test: LRG: p = 0.0079, CRP: p = 0.052, FIT: p < 0.0001, and Fcal: p < 0.0001) (Fig. 2).
The sensitivity, specificity, PPV, NPV, and accuracy of serum/fecal markers in relation to MH were calculated 
for the 166 colonoscopy cases. The AUC for complete MH (MES 0) were LRG: 0.61, CRP: 0.59, FIT: 0.75, and Fcal: 
0.72, respectively. The sensitivity and specificity for complete MH were LRG: 0.78 and 0.47, CRP: 0.87 and 0.18, 
FIT: 0.95 and 0.47, and Fcal: 0.77 and 0.47, respectively (Table 2). The AUC value of LRG was significantly lower 
than those of the two fecal markers (LRG vs. FIT, p = 0.0038, and LRG vs. Fcal, p = 0.039). Sensitivity analysis for 
active inflammation (MES 2 or 3) are shown in Supplemental Table S1.
We analyzed the association of serum/fecal markers with complete MH (MES 0) in UC patients with nor-
mal serum CRP levels (≤ 0.2 mg/dL). The LRG, FIT, and Fcal, levels were associated with complete MH (MES 
0) in 140 patients with normal serum CRP levels (MES 0 vs. MES 1–3: LRG p = 0.018, FIT p < 0.0001, and Fcal 
p < 0.0001) (Supplemental Fig. S1). The AUC for complete MH (MES 0) were LRG: 0.62, FIT: 0.72, and Fcal: 
0.70, respectively. The sensitivity and specificity for complete MH (MES 0) were LRG: 0.87 and 0.41, FIT: 0.94 
and 0.42, and Fcal: 0.76 and 0.41, respectively (Table 3).
Given the above, LRG was considered to be significantly correlated with the endoscopic activity and able to 
predict MH in UC patients, but the correlation and predictability were not superior to those of fecal markers. 
The trends were similar in the analysis of patients with normal CRP levels.
Correlations between serum/fecal biomarkers and histological findings in UC patients. Of the 
total 166 cases, 158 underwent biopsy for pathological examinations and were evaluated with the Geboes score. 
Each serum/fecal biomarker was significantly correlated with histologic activity (Spearman’s rank correlation 
coefficient: LRG: 0.21, p = 0.0091, CRP: 0.17, p = 0.035, FIT: 0.51, p < 0.0001, and Fcal: 0.44, p < 0.0001).
The sensitivity, specificity, PPV, NPV, and accuracy of serum/fecal markers in relation to histological remission 
were calculated with the 158 cases with biopsy. The AUC for histological remission were LRG: 0.65, CRP: 0.61, 
FIT: 0.74, and Fcal: 0.76, respectively. The sensitivity and specificity for histological remission were LRG: 0.79 
and 0.51, CRP: 0.90 and 0.22, FIT: 0.94 and 0.48, and Fcal: 0.81 and 0.50, respectively. Thus, the performance of 

















UC: r = 0.43, p < 0.0001






Crohn’s disease  (CD)
UC: r = 0.29, p = 0.0002
CD: r = 0.42, p = 0.0011
UC: r = 0.25, p = 0.0014
CD: r = 0.61, p < 0.0001
Figure 1.  Correlation between LRG and the other serum/fecal biomarkers in IBD patients. (A) CRP, (B) FIT, 
(C) Fcal. LRG leucine-rich alpha-2 glycoprotein, CRP C-reactive protein, FIT fecal immunochemical test, Fcal 
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Correlations between serum/fecal biomarkers and endoscopic findings in CD patients. The 
correlations between serum/fecal biomarkers and endoscopic findings (mSES-CD) were analyzed. The trend 
between the serum/fecal markers and the mSES-CD was statistically significant (Jonckheere–Terpstra test: LRG: 
p < 0.0001, CRP: p < 0.0001, FIT: p = 0.0004, and Fcal: p < 0.0001) (Fig. 3).
The sensitivity, specificity, PPV, NPV and accuracy of serum/fecal markers in relation to MH were calculated 
for the 56 cases. The AUC for complete MH (mSES-CD 0) were LRG: 0.82, CRP: 0.82, FIT: 0.70, and Fcal: 0.88, 
respectively. The sensitivity and specificity for complete MH were LRG: 0.84 and 0.73, CRP: 0.95 and 0.51, FIT: 
0.95 and 0.43, and Fcal: 0.95 and 0.73, respectively (Table 4). Statistical differences were not observed in AUC 
value between LRG and other markers. The results of sensitivity analysis for MH (mSES-CD 0–2) and active 
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100
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Maximum Mayo score  in the colorectum
13
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0.2
Jonckheere-Terpstra test,  p = 0.0079 Jonckheere-Terpstra test, p = 0.052 
Jonckheere-Terpstra test, p < 0.0001Jonckheere-Terpstra test, p < 0.0001
Figure 2.  Correlation between the serum/fecal biomarkers and maximum MES in UC patients. (A) LRG, 
(B) CRP, (C) FIT, (D) Fcal. MES mayo endoscopic subscore, UC ulcerative colitis, LRG leucine-rich alpha-2 
glycoprotein, CRP C-reactive protein, FIT fecal immunochemical test, Fcal fecal calprotectin. The red dots 
indicate the values of patients with active stage and the blue dots indicate the values of patients with remission 
stage. The specimens with a hemoglobin concentration within this range (0–50 ng/mL) were handled as 
category, because FIT is not accurate for measuring hemoglobin concentrations of < 50 ng/mL. Parallel blue 
lines showed the cutoff values of serum/fecal biomarkers in this study (LRG: 13.0 µg/mL, CRP: 0.20 mg/dL, FIT: 
100 ng/mL, and Fcal: 200 µg/g).
Table 2.  Sensitivity, specificity, and predictive values of the serum/fecal biomarkers for MES 0 in UC patients. 
MES Mayo endoscopic subscore, UC ulcerative colitis, AUC area under curve, PPV positive predictive value, 
NPV negative predictive value, LRG leucine-rich alpha-2 glycoprotein, FIT fecal immunochemical test, Fcal 
fecal calprotectin, CRP C-reactive protein. *The AUC value of LRG was significantly lower than those of the 
two fecal markers (LRG vs. FIT, p = 0.0038, LRG vs. Fcal, p = 0.039).
AUC Sensitivity Specificity PPV NPV Accuracy
LRG 0.61 0.78 (0.69–0.87) 0.47 (0.37–0.58) 0.56 (0.47–0.65) 0.71 (0.60–0.83) 0.61 (0.54–0.69)
CRP 0.59 0.87 (0.80–0.95) 0.18 (0.10–0.26) 0.48 (0.40–0.56) 0.62 (0.43–0.80) 0.50 (0.42–0.58)
FIT 0.75* 0.95 (0.90–1.00) 0.47 (0.37–0.58) 0.61 (0.52–0.70) 0.91 (0.83–0.99) 0.69 (0.62–0.76)
Fcal 0.72* 0.77 (0.67–0.86) 0.47 (0.37–0.58) 0.56 (0.46–0.65) 0.70 (0.58–0.82) 0.61 (0.53–0.68)
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Table 3.  Sensitivity, specificity, and predictive values of the serum/fecal biomarkers for MES 0 in UC patients 
with normal CRP levels (n = 140). Normal CRP: CRP ≤ 0.2 mg/dL. MES Mayo endoscopic subscore, UC 
ulcerative colitis, AUC area under curve, PPV positive predictive value, NPV negative predictive value, LRG 
leucine-rich alpha-2 glycoprotein, FIT fecal immunochemical test, Fcal fecal calprotectin, CRP C-reactive 
protein.
AUC Sensitivity Specificity PPV NPV Accuracy
LRG 0.62 0.87 (0.78–0.95) 0.41 (0.30–0.52) 0.57 (0.48–0.67) 0.77 (0.64–0.90) 0.63 (0.55–0.71)
FIT 0.72 0.94 (0.88–1.00) 0.42 (0.31–0.54) 0.60 (0.50–0.69) 0.89 (0.78–0.99) 0.67 (0.59–0.75)





































Jonckheere-Terpstra test, p < 0.0001
Jonckheere-Terpstra test, p < 0.0001 
Jonckheere-Terpstra test, p < 0.0001Jonckheere-Terpstra test, p = 0.0004
Figure 3.  Correlation between the serum/fecal biomarkers and mSES-CD in CD patients. (A) LRG, (B) 
CRP, (C) FIT, (D) Fcal. mSES-CD modified simple endoscopic score for Crohn’s disease, CD Crohn’s disease, 
LRG leucine-rich alpha-2 glycoprotein, CRP C-reactive protein, FIT fecal immunochemical test, Fcal fecal 
calprotectin. The red dots indicate the values of patients with active stage and the blue dots indicate the values 
of patients with remission stage. The specimens with a hemoglobin concentration within this range (0–50 ng/
mL) were handled as category, because FIT is not accurate for measuring hemoglobin concentrations of < 50 ng/
mL. Parallel blue lines showed the cutoff values of serum/fecal biomarkers in this study (LRG: 13.0 µg/mL, CRP: 
0.20 mg/dL, FIT: 100 ng/mL, and Fcal: 200 µg/g).
Table 4.  Sensitivity, specificity, and predictive values of the serum/fecal biomarkers for mSES-CD 0 in CD 
patients. mSES-CD modified simple endoscopic score for Crohn’s disease, CD Crohn’s disease, AUC area under 
curve, PPV positive predictive value, NPV negative predictive value, LRG leucine-rich alpha-2 glycoprotein, 
FIT fecal immunochemical test, Fcal fecal calprotectin, CRP C-reactive protein.
AUC Sensitivity Specificity PPV NPV Accuracy
LRG 0.82 0.84 (0.68–1.01) 0.73 (0.59–0.87) 0.62 (0.43–0.80) 0.90 (0.79–1.01) 0.77 (0.66–0.88)
CRP 0.82 0.95 (0.85–1.05) 0.51 (0.35–0.67) 0.50 (0.34–0.66) 0.95 (0.85–1.05) 0.66 (0.54–0.78)
FIT 0.70 0.95 (0.85–1.05) 0.43 (0.27–0.59) 0.46 (0.31–0.62) 0.94 (0.83–1.10) 0.61 (0.48–0.74)
Fcal 0.88 0.95 (0.85–1.05) 0.73 (0.59–0.87) 0.64 (0.47–0.82) 0.96 (0.90–1.03) 0.80 (0.70–0.91)
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MH and active inflammation using mSES-CD including the strictures score are shown in Supplemental Tables S4 
and S5.
We analyzed the association of serum/fecal markers with MH in CD patients with normal serum CRP levels 
(≤ 0.2 mg/dL). The LRG and Fcal levels were associated with MH in 36 patients with normal serum CRP levels 
(mSES-CD 0 vs. mSES-CD > 0: LRG p = 0.035, FIT p = 0.31, and Fcal p < 0.0001, respectively) (Supplemental 
Fig. S2). The AUC for complete MH were 0.71, FIT: 0.57, and Fcal: 0.88, respectively. The sensitivity and specific-
ity for mSES-CD 0 were LRG: 0.83 and 0.50, FIT: 0.94 and 0.22, and Fcal: 0.94 and 0.67, respectively (Table 5). 
To precisely evaluate the effect of small bowel lesions, the association of serum/fecal markers with MH was 
analyzed in 20 CD patients who had undergone BAE with normal CRP levels. In this analysis, only Fcal levels 
were associated with MH in these patients (mSES-CD 0 vs. mSES-CD > 0: LRG 10.1 (7.6–12.2) µg/mL vs. 10.2 
(9.0–15.7) µg/mL, p = 0.57, FIT 50 (50–50) ng/mL vs. 50 (50–199) ng/mL, p = 0.068, and Fcal 45.7 (24.7–157) 
µg/g vs. 301 (178 – 919) µg/g, p = 0.0015, respectively).
Thus, LRG was significantly correlated with the endoscopic activity and could predict MH in CD patients, 
and the correlation and predictability were equivalent to those of CRP and Fcal. The sensitivity of LRG for MH 
in CD patients with normal CRP levels was also equivalent to that of Fcal.
Finally, we performed a subanalysis of the correlation between the serum/fecal biomarkers and mSES-CD in 
CD patients according to the disease location (Supplemental Table S6). Spearman’s rank correlation coefficients 
between LRG and mSES-CD according to the disease location were L1: 0.57, p = 0.033, L2: 0.87, p < 0.0001, and 
L3: 0.69, p < 0.0001, respectively. The correlation of LRG appeared to be superior to that of CRP in CD patients 
with colonic involvement (L2: 0.87, p < 0.0001 vs. 0.67, p = 0.0066, and L3: 0.69, p < 0.0001 vs. 0.44, p = 0.021).
Discussion
In the present study, we evaluated the performance of LRG with regard to the predictability of MH in IBD patients 
in the clinical setting and compared our findings with those for CRP and two fecal markers. In UC patients, 
both the correlations with endoscopic activity and predictability of MH of LRG were equivalent to those of CRP 
but not better than those of fecal markers. In CD patients, both the correlations with endoscopic activity and 
predictability of MH were equivalent to those of CRP and Fcal.
Two previous studies have evaluated LRG in UC patients. Serada et al.22. showed increased levels of LRG in 
UC patients, and the values were correlated with the clinical activity better than CRP. However, their study lacked 
an endoscopic evaluation. Shinzaki et al.23 demonstrated that LRG correlated with the clinical and colonoscopic 
activity better than CRP in UC patients, and clinical remission and MH could be discriminated by LRG levels 
even in patients with normal CRP levels.
Compared with those previous reports, there are several strengths associated with the present study. First, the 
performance of LRG was compared to the performance of fecal markers as well as that of CRP. Second, evalua-
tions were performed in not only UC but also CD patients. In CD patients in particular, evaluations of the small 
bowel with BAE were performed if necessary, which is expected to increase the accuracy of the analysis based 
on the endoscopic findings.
Although we confirmed the correlation of the serum levels of LRG with clinical and endoscopic activity and 
its predictability of MH in UC, the performance was not superior to that of CRP. The results were inconsistent 
with those of the previous reports, and the unexpected relatively low correlation and predictability of MH may 
be attributable to the characteristics of our patients. Our cohort included more patients with lower clinical and 
endoscopic activity than previous reports. Indeed, approximately 80% of our patients showed no or mild endo-
scopic activity (MES 0 or 1), while this percentage was 46% (Matts grade 1 or 2) in Shinzaki’s  study23. Because 
the sensitivity of CRP for clinical and/or endoscopic activity was relatively low, the difference in performance 
between LRG and CRP is likely to stand out in cohorts that include more patients with higher activity. The 
previous reports arbitrarily selected patients with various levels of activity to show the performance of LRG; in 
contrast, our patients were consecutively recruited and seem more likely to reflect the actual clinical settings. In 
this context, the clinical usefulness of LRG in the real clinical practice of UC may be more limited than expected.
Although a recent  report36 showed that no significant difference was observed in LRG levels between UC 
patients and healthy individuals, some attributes including age, sex, and BMI could affect the values of LRG. In 
fact, the associations of CRP and Fcal with these attributes have been  reported37–41. Although the adjustment 
according to those variables could not be performed due to insufficient data in our analysis, older women may be 
likely to have higher LRG levels. In fact, of 10 patients (7 UC patients and 3 CD patients) who showed complete 
MH with an elevated LRG level (> 13 µg/mL) but with normal CRP (≤ 0.20 mg/dL) and normal Fcal (≤ 200 µg/g), 
9 were women over 40. Further data collection is required for attributes that affect LRG.
Table 5.  Sensitivity, specificity, and predictive values of the serum/fecal biomarkers for mSES-CD 0 in 
CD patients with normal CRP levels (n = 36). Normal CRP: CRP ≤ 0.2 mg/dL. mSES-CD modified simple 
endoscopic score for Crohn’s disease, CD Crohn’s disease, AUC area under curve, PPV positive predictive 
value, NPV negative predictive value, LRG leucine-rich alpha-2 glycoprotein, FIT fecal immunochemical test, 
Fcal fecal calprotectin, CRP C-reactive protein.
AUC Sensitivity Specificity PPV NPV Accuracy
LRG 0.71 0.83 (0.66–1.01) 0.50 (0.27–0.73) 0.63 (0.43–0.82) 0.75 (0.51–1.00) 0.67 (0.51–0.82)
FIT 0.57 0.94 (0.84–1.05) 0.22 (0.03–0.41) 0.55 (0.37–0.72) 0.80 (0.45–1.15) 0.58 (0.42–0.74)
Fcal 0.88 0.94 (0.84–1.05) 0.67 (0.45–0.88) 0.74 (0.56–0.92) 0.92 (0.78–1.07) 0.81 (0.68–0.93)
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Because cytokines other than IL-6 are also involved in LRG production, the possible influence on the value of 
LRG under TNFα antagonist was concerned. Hence, we compared AUC value of the serum/fecal biomarkers for 
complete mucosal healing between IBD patients with and without TNFα antagonist (Supplemental Table S7). In 
UC patients, AUC of LRG in patients with TNFα antagonist was not superior to that in patients without TNFα 
antagonist. In CD patients, on the other hand, AUC of LRG in patients with TNFα antagonist was numerically 
higher than AUC in patients without TNFα antagonist. Because the patient numbers were limited in this regard, 
additional examinations would be needed in the future.
Few reports have compared the performance of LRG to that of fecal markers based on endoscopic findings. 
Our results clearly demonstrated that, in UC patients, both fecal markers (Fcal and FIT) were correlated with 
the endoscopic activity and predicted MH better than LRG. Previous reports have indicated that the correlation 
with the endoscopic activity and predictability of MH of fecal markers was better than that of  CRP4,7–9. Because 
the performance of LRG was not superior to that of CRP in UC patients in the present study, the superiority of 
fecal markers to LRG is considered reasonable. However, the performance of LRG may also have been under-
estimated due to the characteristics of our cohort, which included more patients with a lower disease activity 
than previous studies.
In this study, we examined the performance of LRG in CD patients, and the correlation with the endoscopic 
activity and predictability of MH of LRG were quite similar to those of CRP and comparable to those of Fcal. 
The AUCs of both serum markers were higher in CD than in UC. Thus, LRG as well as CRP may be useful for 
evaluating the disease activity and MH in CD patients, even without fecal tests. In addition, the performance of 
LRG appears to be superior to that of CRP in CD with colonic involvement. Therefore, LRG might be particularly 
useful in CD patients with colonic involvement.
In clinical practice of IBD, the evaluation of the disease activity in patients with normal CRP has been chal-
lenging. We therefore evaluated the performance of LRG as well as that of fecal markers in UC and CD patients 
with normal CRP levels. LRG was able to discriminate patients with MH from those with endoscopic activity 
among both UC and CD patients, as previously shown in UC by Shinzaki et al.23. However, the performance of 
LRG did not surpass that of fecal markers, and in particular, the specificity for MH appeared to be insufficient. 
Because our cohort included more patients with a lower disease activity, fecal markers may be preferable to LRG 
to stratify patients with a lower disease activity.
We found no distinct advantage of LRG over CRP or fecal markers in our cohort, which included more 
patients with a low disease activity than previous  studies22,23 and largely reflected real clinical practice of IBD. 
However, serum markers are more convenient to measure for both patients and physicians, and the values of 
LRG had wider range than those of CRP, suggesting that LRG may be more suitable for evaluating fluctuations 
in the disease activity than CRP.
The present study is associated with some limitations. First, common drawbacks are the relatively small 
number of patients and the single-institution design. Second, the effect of concomitant diseases that can poten-
tially increase LRG, such as subtle arthritis, asymptomatic cold, and sinusitis, were not fully evaluated. Third, 
the small intestine in CD patients was assessed using transanal BAE, and inflammation in the deeper ileum or 
jejunum might not have been observed. Finally, more patients in the remission stage or with a lower disease 
activity were included in this study than in previous  studies21,23, which might have led to results with an insuf-
ficient performance of LRG. However, our cohort was consecutively recruited and is expected to largely reflect 
real clinical practice of IBD.
In conclusion, LRG was correlated with the endoscopic activity and able to predict MH in clinical practice in 
both UC and CD patients. In UC, however, the performance was not superior to that of fecal markers, whereas 
in CD, LRG, CRP, and Fcal were equivalently useful. Further experiences and examinations will be required to 
utilize this new serum marker efficiently in clinical practice of IBD.
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